<DOC>
	<DOC>NCT00344773</DOC>
	<brief_summary>The purpose of this study is to evaluate the overall objective tumor response rate (ORR) of Gefitinib.</brief_summary>
	<brief_title>First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Patients require histological biopsy and paraffin block more than 5mg from the original tumour or metastatic site to perform EGFR mutational analysis WHO Performance Status 02 No prior chemotherapy, biological or immunological therapy/surgery Any evidence of clinically active interstitial lung disease Newly diagnosed CNS metastases that have not yet been definitively treated with surgery /radiation Patients with previously diagnosed and treated CNS metastases or spinal cord compression</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Locally advanced (IIIB) pulmonary adenocarcinoma with EGFR mutation</keyword>
	<keyword>Metastatic (IV) pulmonary adenocarcinoma with EGFR mutation</keyword>
	<keyword>Recurrent pulmonary adenocarcinoma with EGFR mutation</keyword>
</DOC>